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Current therapies for prostate cancer include antiandro-
gens, inhibitory ligands of the androgen receptor, which
repress androgen-stimulated growth. These include the
selective androgen receptor modulators cyproterone ac-
etate and hydroxyflutamide and the complete antagonist
bicalutamide. Their activity is partly dictated by the pres-
ence of androgen receptor mutations, which are com-
monly detected in patients who relapse while receiving
antiandrogens, i.e. in castrate-resistant prostate cancer.
To characterize the early proteomic response to these
antiandrogens we used the LNCaP prostate cancer cell
line, which harbors the androgen receptor mutation most
commonly detected in castrate-resistant tumors (T877A),
analyzing alterations in the proteome, and comparing
these to the effect of these therapeutics upon androgen
receptor activity and cell proliferation. The majority are
regulated post-transcriptionally, possibly via nongenomic
androgen receptor signaling. Differences detected be-
tween the exposure groups demonstrate subtle changes
in the biological response to each specific ligand, sug-
gesting a spectrum of agonistic and antagonistic effects
dependent on the ligand used. Analysis of the crystal
structures of the AR in the presence of cyproterone ace-
tate, hydroxyflutamide, and DHT identified important dif-
ferences in the orientation of key residues located in the
AF-2 and BF-3 protein interaction surfaces. This further
implies that although there is commonality in the growth
responses between androgens and those antiandrogens
that stimulate growth in the presence of a mutation, there
may also be influential differences in the growth pathways
stimulated by the different ligands. This therefore has
implications for prostate cancer treatment because tu-
mors may respond differently dependent upon which mu-
tation is present and which ligand is activating growth,
also for the design of selective androgen receptor modu-
lators, which aim to elicit differential proteomic responses
dependent upon cellular context. Molecular & Cellular
Proteomics 14: 10.1074/mcp.M113.036764, 1201–1216,
2015.
Prostate tumors are dependent upon the androgen recep-
tor (AR)1 for growth. The AR is a ligand-activated transcription
factor that promotes prostate cancer growth through genomic
and nongenomic actions. In the canonical genomic pathway,
the AR regulates transcription following interaction with spe-
cific DNA sequences, termed androgen response elements, in
the regulatory regions of target genes (1). More recently, it has
been demonstrated that cytoplasmic AR, within minutes of
activation, also stimulates kinase signaling cascades (e.g.
ERK and PI3K) and that this nongenomic signaling is also
important in proliferation (2). The first line of treatment for
nonlocalized, therefore, inoperable disease is androgen
blockade. This involves chemical castration to reduce testic-
ular production of androgens and administration of antiandro-
gens, which bind to the AR and hold it in an inactive state.
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Hormone therapy is initially successful in the majority of
patients (3), but invariably fails after a median period of 13
months, growth recurs and the disease proceeds to castrate
resistance (CRPC). Multiple mechanisms have been proposed
to explain CRPC and much evidence exists to suggest that
even in the androgen-depleted environment, the AR continues
to drive growth (4). For example, mutations of the AR have
been detected in 2–25% of hormone sensitive tumors and
10–40% of cases of hormone refractory disease (5). These
mutations appear to be the result of selective pressure in-
duced by the treatment itself and in some cases the mutant
receptors can be activated by alternative ligands, including
antiandrogens used in therapy (6). The majority of mutations
identified to date cluster in the ligand binding domain (LBD) of
the receptor (4) and of those that have been studied at the
functional level, several appear to offer a growth advantage
because of reduced ligand specificity, enhanced androgen
sensitivity, or constitutive activity (6–10). Other studies have
determined the responses of prostate cancer cells to various
ligands of the AR and it has been demonstrated that ligand-
specific gene regulation by the AR can occur (11–13).
The most frequently reported mutation, associated with
prostate cancer, is a substitution of threonine to alanine at
amino acid 877 (T877A). The T877A mutation appears to be
more prevalent in patients who relapse following treatment
with the antiandrogen hydroxyflutamide (6) and when com-
pared with the wild-type receptor, this mutant has increased
transcriptional activity in the presence of other steroid hor-
mones, such as estradiol and progesterone and also the
antiandrogens cyproterone acetate and hydroxyflutamide
(14). This activation by antiandrogens is not universal, as the
antiandrogen bicalutamide is able to block activity of this
mutant (15). To determine the extent to which proteomic
responses to androgens and antiandrogens overlap in the
presence of this mutant receptor, we exposed the LNCaP
prostate cancer cell line, which harbors the T877A AR variant,
to the dihydrotestosterone (DHT) analog mibolerone, cyprot-
erone acetate, hydroxyflutamide, and bicalutamide. 2-Dimen-
sional polyacrylamide gel electrophoresis (2-DE) was used to
determine protein regulation in whole cell lysates and sets of
regulated proteins were compared. Characterization of the
proteomic response to antiandrogen exposure will provide
further insight into the phenomenon of receptor promiscuity in
CRPC and also highlight future targets for therapy once anti-
androgen resistance has occurred.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatments—HeLa cells and the LNCaP prostate
cancer cell line were obtained from ATCC and cultured at 37 °C, 5%
CO2 in Dulbecco’s modified Eagle’s medium (DMEM) and Roswell
Park Memorial Institute (RPMI) medium 1640 (Invitrogen, Strathclyde,
UK) respectively, both supplemented with 2 mM L-Glutamine,
100units/ml penicillin, 100 mg/ml streptomycin (Sigma Aldrich, St
Louis, MO) and 10% fetal bovine serum. The LNCaP-PHB cell line has
been previously described (16) and was grown in media supple-
mented as above with the exception that 10% tetracycline-free fetal
bovine serum was used and the cells additionally supplemented with
12 g/ml blasticidin (Invitrogen, Carlsbad, CA), 500 g/ml G418
(Sigma-Aldrich), and 0.3 mg/ml zeocin (Invitrogen).
Mibolerone (Perkin-Elmer, Beaconsfield, UK), cyproterone acetate
(Sigma-Aldrich, Dorsett, UK), bicalutamide (Astra-Zeneca, Cheshire,
UK), and hydroxyflutamide (Schering-Plough, Hertfordshire, UK) were
resuspended in ethanol and stored at 20 °C until use, final concen-
trations were 10 nM for mibolerone and 1 M for antiandrogens.
Reporter Assays—HeLa cells were grown to 60% confluence in
phenol red free media containing 5% double charcoal stripped se-
rum, in 24-well plates. After 24 h, cells were transfected using
FuGENE 6 (following the manufacturers instructions) with 100 ng wild
type or mutant pSV-AR, 100 ng PDM-LAC-Z--GAL, and 1 g of
luciferase reporter (TAT-GRE-E1B-LUC) per well. Eighteen hours
post-transfection cells were treated with ligand for 24 h. Luciferase
and -galactosidase expression was quantified as previously de-
scribed (14).
Cell Proliferation Assay—LNCaP cells were plated at a density of
104 cells per well in 96-well plates in RPMI. After 16 h incubation, the
wells were washed twice in phosphate buffered saline (PBS) before
incubation for 48 h in phenol-red free RPMI supplemented with 5%
charcoal stripped FBS, 2 mM L-Glutamine, 100units/ml penicillin, and
100 mg/ml streptomycin. Hormone was subsequently directly to the
media cells incubated for a further 72 h. To measure cellular prolifer-
ation, mitochondrial dehydrogenase activity was assayed using the
WST-1 reagent (Roche Applied Science Ltd, Hertfordshire, UK) as per
manufacturer’s instructions. Eight wells were assayed per condition in
each of three independent experiments.
2-Dimensional Gel Electrophoresis (2-DE)—Five samples were pre-
pared per experimental condition. 25 cm2 flasks of LNCaP cells were
transferred to phenol red-free RPMI supplemented with 2 mM L-Glu-
tamine, 100units/ml penicillin, 100 mg/ml streptomycin, and 10%
charcoal stripped fetal bovine serum for 48 h before exposure to
hormone or ethanol. Hormone was added to the media and mixed
thoroughly. Cells were incubated as above for 16 h, then placed on
ice and washed twice in PBS before lysis in 200 l isoelectric focusing
buffer. Isoelectric focusing (IEF) was performed using immobilized pH
gradient (IPG) strips (GE Healthcare, Amersham Biosciences, UK), of
pH range 3–10 (linear). The solubilized protein sample was applied to
the strips during gel rehydration, according to the manufacturer’s
instructions. The samples were diluted with rehydration solution con-
taining 8 M urea, 0.5% CHAPS, 0.2% DTT, and 0.2% Pharmalyte (pH
3–10) prior to loading, total protein loaded was 250 g in 450 l. The
strips were focused at 0.05 mA/IPG strip for 60 kVh at 20 °C. After
IEF, the strips were equilibrated in 1.5 M Tris, pH 8.8, buffer containing
6 M urea, 30% glycerol, 2% SDS, and 0.01% bromphenol blue, with
the addition of 1% DTT for 15 min, followed by the same buffer with
the addition of 4.8% iodoacetamide for 15 min. SDS-PAGE was
performed using 12% T, 2.6% C separating polyacrylamide gels
without a stacking gel, using the Iso-Dalt system (GE Healthcare). The
second-dimension separation was carried out overnight at 20 mA/gel,
15 °C and was stopped when the bromphenol blue dye-front was 1
cm from the bottom of the gels.
Protein Spot Imaging and Gel Image Analysis—The dye front on
each gel was removed using a scalpel blade and the gels fixed in 40%
methanol 10% acetic acid for 1 h. Gels were then incubated in
Sypro-ruby protein stain (GE Healthcare) overnight then washed in
distilled water for 30 min. Stained gels were scanned using a Typhoon
phosphorimager on fluorescent mode (GE Healthcare) and analytical
images were analyzed using PDQuest version 8 (Bio-Rad, Hemel
Hempstead, UK). After detection of spots, the gels were aligned,
landmarked and matched. Gels were then placed into the appropriate
experimental class and differential analysis performed. The student t
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test was used to detect all spots that differed significantly between
the control and exposed groups (p  0.05), all significantly different
spots were then checked manually to eliminate any artifactual differ-
ences because of gel pattern distortions and inappropriately matched
or badly detected spots.
Mass Spectrometry—Proteins spots of interest were excised man-
ually from gels and subjected to in gel digestion with trypsin as
described previously (17). Tandem mass spectra were recorded using
a Q-Tof spectrometer (Waters, Manchester, UK) interfaced to a Wa-
ters CapLC capillary chromatograph. Samples were dissolved in
0.1% formic acid and injected onto a 300 m  5 mm Pepmap C18
column (LC Packings, Amsterdam, NL) and eluted with an acetoni-
trile/0.1% formic acid gradient. The capillary voltage was set to 3500
V. A survey scan over the m/z range 400–1300 was used to identify
protonated peptides with charge states of 2, 3, or 4, which were
automatically selected for data-dependent MS/MS analysis, and frag-
mented by collision with argon. The resulting product ion spectra
were transformed onto a singly charged m/z axis using a maximum
entropy method (MaxEnt3, Waters) and proteins were identified by
correlation of uninterpreted spectra to entries in SwissProt/TrEMBL,
using ProteinLynx Global Server (Version 2.2, Waters). The database
was created by merging the FASTA format files of SwissProt
(2012_09 release), TrEMBL, and their associated splice variants
(1,768,175 entries at the time of searching). No taxonomic or protein
mass and pI constraints were applied. One missed cleavage per
peptide was allowed, and the initial mass tolerance window was set
to 100 ppm. For further confirmation of the identifications, the spectra
were also searched against the NCBI nr database (4,496,228
sequences as of January 2007) using Mascot v.2.2 (www.
matrixscience.com) (18). For an identification to be considered valid
we required two or more peptides were identified, that the peptide
score was significant (typically greater than 55 (p  0.05)), and that
manual interpretation confirmed agreement between spectrum and
peptide sequence. In addition, Mascot searches of all spectra were
performed against a randomized version of the NCBI database using
the same parameters as in the main search. In no case did this search
retrieve more than a single peptide, and in all instances, the peptide
score was below the 0.05 significance level.
Immunoblotting—Cells were treated and incubated as indicated,
washed in PBS and harvested by cell scraping. Cells were pelleted
(1200 rpm, 4 min), lysed in 9 M Urea and protein concentrations
determined using a modified Bradford Assay (19) (Bio-Rad, Hemel
Hempstead, UK). SDS-PAGE and immunoblotting was performed as
described previously (20) using the following antibodies: Anti-AR
(N-20, Santa Cruz Biotechnology, Dallas, TX); Anti-Flag (M-2, Sigma
Aldrich) and -actin (AC-15, Abcam, Cambridge, UK).
Real-Time Quantitative PCR—Cells were grown in hormone-de-
pleted media for 72 h and treated with ligand for 16 h. RNA was
extracted using TRI-Sure reagent (Bioline, Taunton, MA) and a DNase
step included (Thermo Scientific, Leicestershire, UK). Reverse tran-
scription was performed using the nanoScript RT Kit (Primer Design,
Southampton, UK). Alterations in gene expression were quantitifed
using a qPCR (Roche LightCycler 96, Roche, IN).
Comparison of AR Crystal Structures—Crystal structures retrieved
from the Protein Data Bank were superposed using a “secondary
structure matching” algorithm implemented in the program Super-
pose (21) within the CCP4 suite (22). Figures were prepared using
PyMol (23).
RESULTS
Confirmation of Growth and Transcriptional Responses to
Androgen and Antiandrogens in the LNCaP Cell Line—It is
well documented that AR containing the T877A substitution
has reduced ligand specificity, allowing it to be activated by a
range of compounds that repress or do not fully activate the
wild-type receptor (4). In order to determine the extent of this
activation for the ligands under investigation, we carried out
transcriptional activation assays comparing wild-type AR and
ART877A in AR negative HeLa cells, and cell growth assays in
LNCaP cells, in the presence of the synthetic androgen mi-
bolerone (a nonmetabolisable analog of the natural ligand
DHT, with the same relative binding affinity (24, 25)), the
partial agonists cyproterone acetate and hydroxyflutamide,
and the pure antagonist, bicalutamide. The relative binding
affinities of the latter three ligands for wild-type AR are be-
tween 1 and 6% as compared with DHT (24, 26) (supplemen-
tal Fig. S1).
Immunoblotting confirmed equal expression of the wild-
type and mutant AR in transfected cells (Fig. 1A). Wild-type
AR and ART877A were activated to a similar extent in the
presence of the higher concentrations of mibolerone (Fig. 1B)
and in keeping with previous studies, ART877A was found to
have higher levels of activity when compared with wild-type
AR in the presence of cyproterone acetate and hydroxyflut-
amide, whereas bicalutamide did not activate either of the
receptors. To investigate whether this altered transcriptional
profile correlated with cell growth driven by ART877A, prolifer-
ation assays were performed. The LNCaP cell line was cul-
tured in the presence of 10 nM Mibolerone or 1 M antiandro-
gen for 72 h. As expected, the growth observed in response to
the different ligands correlated with transcriptional response
(Fig. 1C); mibolerone, cyproterone acetate, and hydroxyflut-
amide all induced similar increases in growth that were sig-
nificantly greater than that observed in untreated control cells,
whereas no change in growth was evident following treatment
with bicalutamide.
Regulation of Protein Features Following Exposure to An-
drogens and Antiandrogens in LNCaP Cells—The first set of
2-DE experiments was intended to characterize the “pure”
androgen- and antiandrogen-related responses at the pro-
teome level. Cells were treated with vehicle (Ethanol, EtOH),
mibolerone or bicalutmide for 16 h. Five individual protein
samples were subjected to 2-DE per treatment and between
419 and 997 protein features were detected across the gels.
Of these features, between 320 and 698 were matched across
the data set and 286 were matched to all 15 gels (Fig. 2A).
PDQuest analysis detected 34 protein features regulated in
comparison to ethanol controls, using student t test with 95%
confidence limits, with examples of proteins being both up
and down regulated and some with multiple isoforms being
regulated (Table I and examples in Fig. 2B and 2C). Of the
regulated proteins, 12 were regulated only by mibolerone, 17
by bicalutamide, and five were regulated by both (Fig. 2D).
We next determined the extent to which exposure of the
LNCaP cells to the partial agonists cyproterone acetate and
hydroxyflutamide correlated with the responses to pure an-
drogen or antiandrogen observed in the first experiment.
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Again, five protein samples were processed per condition
(vehicle, mibolerone, cyproterone acetate, and hydroxyflut-
amide). The 2D gels contained between 360 and 589 protein
features, and in total 241 features were matched across all
gels (Fig. 3A). PDQuest analysis detected 38 protein features
regulated in comparison to ethanol controls, using student t
test with 95% confidence limits (Fig. 3B and 3C). Of these, 15
were regulated by mibolerone, 25 by cyproterone acetate,
and 17 by hydroxyflutamide (Fig. 3D and Table I). Overlap
between groups was greatest for features regulated by both
hydroxyflutamide and cyproterone acetate, with 12 proteins
being commonly regulated. Five proteins were commonly reg-
ulated between cyproterone acetate and mibolerone treated
cells, whereas three were regulated in common between hy-
droxyflutamide and mibolerone. Only one protein feature was
shown to be commonly regulated between all three exposure
groups.
Protein Identities of Regulated Features—Mass spectrom-
etry of regulated protein features resulted in identification of a
total of 36 proteins, excluding hits where fewer than two
peptides were positively identified (Table I). Proteins were
submitted to Gene Ontology analysis (Scaffold) to identify key
processes/functions regulated by the AR pathway. Similar to
previous studies (e.g. (27)), the largest ontology grouping
found to be regulated by the AR was Metabolic Processing
(Fig. 4).
FIG. 1. Effect of T877A substitution
on AR activity and cell growth in the
presence of androgens and antian-
drogens. A, Expression levels of the
transfected wild-type and T877A mutant
androgen receptors. Cells were trans-
fected with expression vector for either
the wild-type AR or ART877A and a flag-
tagged control plasmid (to control for
transfection efficiency). The empty lane
refers to cells transfected with empty
plasmid. Cells were lysed and proteins
visualized by Western blotting. Blots
were probed with anti-AR and re-probed
with antiflag and -actin antibodies. B,
HeLa cells were transiently transfected
with expression vector for either the wild-
type AR or ART877A mutant, TAT-GRE-
E1B-LUC luciferase reporter and a -ga-
lactosidase expression vector. Cells were
exposed to ligand for 16 h. Luciferase ac-
tivities were normalized for -galactosid-
ase activity and expressed as a percent-
age of the wild-type receptor activity in
the presence of 107 M MIB. Data pre-
sented are the mean of three independent
experiments performed in duplicate 
S.D. C, LNCaP cells were exposed to 10
nM mibolerone, or 1 M antiandrogen, for
72 h and proliferation measured using
WST-1 assays. Representative data of
three individual experiments is presented,
bars are means S.D. of eight replicates.
ANOVA Tukey: * p 0.05, ** p 0.005,
*** p  0.001. Significant differences are
comparison between AR wild-type and
AR T877A in B, and between EtOH and
ligands in C,. ETOH, ethanol; MIB, mibo-
lerone; CPA, cyproterone acetate; OHF,
hydroxyflutamide; BIC, bicalutamide.
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Proteins regulated by mibolerone were associated with a
wide spectrum of functions and pathways, including cell cycle
regulation (e.g. prohibitin), protein folding (e.g. protein disul-
fide isomerise 6), ATP synthesis (e.g. ATP-synthase alpha
chain), and gene transcription (e.g. Protein DJ-1). Proteins
regulated in common between mibolerone and the antiandro-
gens were included in many of these same pathways and
included the antioxidant defense enzymes catalase and per-
oxidoredoxin 2 (Table I). Generally, proteins down-regulated
by bicalutamide tended to be involved in metabolic or protein
synthesis pathways (e.g. lactoglutathione lyase and Methyl-
malonate-semialdehyde dehydrogenase) or antioxidant de-
fense (e.g. peroxidoredoxin 4).
The AR Targets Are Predominantly Regulated at the Post-
transcriptional Level—To investigate whether the target pro-
teins are regulated at the transcriptional level, LNCaP cells
were treated with ligand for 16 h, RNA harvested, and qPCR
performed for a selection of the protein-encoding genes iden-
tified (Fig. 5). As a positive control, we confirmed mibolerone,
cyproterone acetate, and hydroxyflutamide induction of the
known AR target kallikrein 2 (KLK2). No significant change in
expression was evident for the targets, with the exception of
glutamate dehydrogenase (GLUD1), which was found to be
up-regulated threefold in response to mibolerone and weakly
upregulated in response to cyproterone acetate snd hydroxy-
flutamide. It therefore appears that the majority of alterations
in the proteome in response to androgen receptor activation/
inhibition, at this early time point, are at the post-transcrip-
tional level.
The Androgen Down-regulated Target Prohibitin: A Sup-
pressor of Cell Growth—Androgen signaling is a key driver of
prostate cancer growth and as such, factors regulated by the
AR are likely to be important in proliferation. An example of
this is Prohibitin (PHB), which we have demonstrated to be
FIG. 2. 2-DE profile of cell extract from LNCaP exposed to mibolerone and bicalutamide. LNCaP cells in culture were exposed to 10
nM mibolerone, or 1 M antiandrogen, for 16 h. A, Filtered, inverted, fluorescent gel image of gel used as master gel. Cell lysates were subjected
to IEF over a linear range of pI 3–10 and 12% PAGE on 24 cm gels. Differential regulation of protein features was detected using PDQuest
software using student t test (p  0.05). B, regulation of protein features by exposure to androgen and antiandrogen. Images are filtered
inverted fluorescent gel images of individual gels; regulated protein features are highlighted with arrows. C, graphical representation of
regulated protein features. Data shown represents mean  S.D. of fluorescence intensity recorded for each gel, n  5 (samples from
independent studies). D, Venn diagram of numbers of regulated protein features. ETOH, ethanol; MIB, mibolerone; BIC, bicalutamide. T-Test:
*** p  0.001. Significant differences are comparison between EtOH and other ligands.
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androgen-regulated and to regulate LNCaP proliferation (data
herein and (28)). PHB was found to be down-regulated in
response to androgen, with little change evident in response
to cyproterone acetate, hydroxyflutamide, or bicalutamide
(Fig. 6A). We were interested to see if PHB could block LNCaP
growth activated not only by androgen but also by cyprot-
erone acetate and hydroxyflutamide. To perform this experi-
ment, we utilized the LNCaP cell line stably transfected with
the PHB gene under the control of the doxycycline promoter
(29). Cells were plated in hormone-depleted media and
treated with concentration ranges of mibolerone, bicalut-
amide, hydroxyflutamide, or cyproterone acetate  doxycy-
cline and proliferation assessed after 4 days. As expected,
increasing concentrations of mibolerone, cyproterone ace-
tate, and hydroxyflutamide promoted cell growth (Fig. 6B–
6D), whereas bicalutamide had no effect on proliferation (Fig.
6E). Over-expression of PHB was found to significantly block
the growth promoting effects of mibolerone with no significant
increase in growth evident at any concentration of mibolerone
(ANOVA, p 	 0.05). In contrast, PHB was less efficient at
inhibiting the growth promoting effects of hydroxyflutamide
and cyproterone acetate (41 and 67% inhibition of AR activity,
respectively, compared with 94% in presence of MIB) sug-
gesting that the inhibitory effects of PHB are dependent upon
the ligand driving growth (Fig. 6C–6D).
The Different Ligands Are Associated with Different Confor-
mations in the AR AF-2 and BF-3 Interaction Domains—To
investigate potential mechanisms by which ART877A pro-
motes ligand-dependent alterations in the proteome of
LNCaP cells, we undertook detailed analysis of the available
crystal structures of the ART877A ligand-binding domain in
the presence of DHT (PDB accession number 1i38), cypro-
terone acetate (2oz7), or hydroxyflutamide (2ax6). The AF-2
and BF-3 regions of the AR are known interaction sites for
FIG. 3. 2-DE profile of cell extract from LNCaP exposed to mibolerone and antiandrogens. LNCaP cells in culture were exposed to 10
nM mibolerone, or 1 M antiandrogen, for 16 h. A, Filtered, inverted, fluorescent gel image of gel used as master gel. Cell lysates were subjected
to IEF over a linear range of pI 3–10 and 12% PAGE on 24 cm gels. Differential regulation of protein features was detected with PDQuest
software using student t test (p  0.05). B, regulation of protein features by exposure to androgen and antiandrogen. Images are Gaussian,
inverted, fluorescent, gel images of individual gels; regulated protein features are highlighted with arrows. C, graphical representation of
regulated protein features. Data shown represents mean  S.D. of fluorescence intensity recorded for each gel, n  5 (samples from
independent studies). D, Venn diagram of numbers of regulated protein features. ETOH, ethanol; MIB, mibolerone; CPA, cyproterone acetate;
OHF, hydroxyflutamide. T-Test: * p  0.05, **p  0.005, *** p  0.001. Significant differences are comparison of EtOH and other ligands.
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cofactors and hence our analysis focused on these regions
(Fig. 7A) (30–32).
The AF-2 surface of the AR ligand-binding domain consists
of a hydrophobic cleft with charged clamp residues (Lys 720
and Glu 897) positioned at either end of the groove (14, 33).
Alpha-helical motifs found in coactivators bind to this groove
and form interactions with the highlighted residues (Fig. 7B)
(30, 34). The majority of residues within the AF-2 region are
similar in position in all three structures (Fig. 7B and 7C).
However, the side chain positions of residues Met734,
Asp731, and Met894 are similar for cyproterone acetate and
hydroxyflutamide, but differ to that evident for the DHT com-
plex. The shift in the Met894 position in the DHT complex in
particular results in the side chain aligning within the groove,
significantly reducing its size. The charge clamp residue
Glu897 exhibits significant variability, with a different orienta-
tion in the hydroxyflutamide complex compared with that in
the other two structures.
The BF3 domain of the AR is an allosteric pocket that has
also been demonstrated to be important in receptor function
and protein interactions (30, 32). In the case of the BF3
domain, fewer differences are apparent between the three
structures although the side chain of Glu 829 occupies a
different rotamer in the DHT complex compared with the other
structures, with Arg 840 being differently positioned in all
structures (Fig. 7C). In summary, the conformation of the AF-2
and BF-3 surfaces are most similar when the receptor is in
complex with SARMs cyproterone acetate and hydroxyflut-
amide, however, differences in conformation are apparent for
all ligands investigated.
DISCUSSION
Resistance of prostate cancer to hormone therapy is a
common occurrence in patients exposed to long-term treat-
ment. Multiple mechanisms have been proposed to explain
therapy relapse, including mutation of the AR resulting in
constitutively or promiscuously active receptor. The reported
frequency of AR mutation in recurrent prostate cancer varies
greatly between studies, ranging from 10–50%, but incidence
does appear to correlate with therapy resistance (4, 5, 35).
One mutation detected in the AR of prostate cancer patients
is a substitution of threonine to alanine at amino acid 877 (6),
which is also present in the LNCaP prostate cancer cell line. In
this study, we investigated the proteomic response of the
LNCaP cell line in response to an androgen, the activating
antiandrogens cyproterone acetate and hydroxyflutamide and
bicalutamide, which remains antagonistic to LNCaP growth
(36). The synthetic DHT analog mibolerone was used through-
out the study because DHT is rapidly metabolized and inac-
tivated in LNCaP cells (37); studies using androgen analogs
have shown a high degree of overlap with DHT response
demonstrating that the action of these synthetic ligands is
comparable with the natural ligand (38).
The ART877A variant is known to be activated by several
antiandrogens, including cyproterone acetate and hydroxy-
FIG. 4. Gene Ontology analysis of
proteins regulated by the androgen
receptor. Biological processes were as-
signed using Scaffold Viewer (Proteome
Software Portland, OR).
FIG. 5. The AR target proteins are predominantly regulated at
the post-transcriptional level. LNCaP cells were grown in steroid-
depleted media for 72 h and treated with ligand for 16 h. RNA was
harvested, reverse transcriped, and qPCR performed to investigate
alterations in relative gene expression. Gene expression was normal-
ized to L19 expression. Mean of four repeats 1sd. T-Test * p 0.05.
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flutamide, and thus we have used it to determine the early
proteomic responses to such ligands versus the response to
androgen. Using WST1 proliferation assays (succinate dehy-
drogenase activity as a surrogate for proliferation) we con-
firmed that mibolerone and the antiandrogens cyproterone
acetate and hydroxyflutamide promote growth of LNCaP
cells. We note that our proteomic results demonstrated that
the AR regulates a number of proteins involved in metabolism,
however, the expression of succinate dehydrogenase was not
found to be regulated in response to any of the ligands tested
and our WST1 results correlate with similar proliferation stud-
ies that have utilized alternative methods to assess cell
growth (e.g. (15, 39)).
This study has demonstrated that different ligands largely
regulate different subsets of proteins, although some degree
of overlap was detected between the two partial agonists and
mibolerone. Interestingly, more than half of the mibolerone-
regulated proteins identified here have been previously shown
to be androgen regulated in proteomic studies of the LNCaP
cell line (12, 27, 40, 41). Of note, our study identified fewer
androgen target proteins than these previous studies, which
may be explained by the shorter treatment time (16 h as
opposed to 48–72 h) resulting in fewer indirect androgen
protein targets being significantly regulated. In contrast, 80%
of proteins regulated by cyproterone acetate and/or hydroxy-
flutamide, were not identified in these previous studies, sup-
porting the supposition that these ligands promote an alter-
native proteomic response compared with the cognate ligand.
The overlapping responses between androgen and the acti-
vating antiandrogens are of particular importance because
they may therefore represent truly agonistic responses of the
liganded receptor. Unsurprisingly, the largest differences
were detected between cells exposed to the agonist mibo-
lerone and the pure antiandrogen, bicalutamide. Following
bicalutamide treatment, the majority of responsive proteins
were down-regulated. These included proteins involved in
protein synthesis, glycolysis, and cell signaling, such as lac-
toglutathione lyase and Ran specific GTPase activating pro-
tein. Exceptions to this observation included 75 kDa heat
shock protein (HSP75), also known as TRAP1 (tumor necrosis
factor receptor-associated protein-1), which was up-regu-
lated by bicalutamide. TRAP1 has antiapoptotic functions and
plays a role in multidrug resistance in colorectal carcinoma
(42). The up-regulation of TRAP1 in response to bicalutamide
FIG. 6. Prohibitin selectively blocks androgen induced prostate cancer growth. A, LNCaP cells were grown in hormone-depleted
medium for 48 h and treated with 10 nM mibolerone or 1 M antiandrogen, or equivalent volume of ethanol for 16 h. Protein lysates were
separated by Western blotting and visualized using immunodetection and densitometry performed (mean of three independent repeats  1
S.D.). T-Test * p  0.05. (B–D) the LNCaP-PHB cell line was grown in hormone-depleted medium for 72 h, treated with ligand for 96 h and
proliferation assessed using WST1 assays. Mean of three independent replicates  1 S.D. ANOVA * p  0.05, ** p  0.005, *** p  0.001.
Significant differences are comparison of EtOH and other ligands in a, and comparison of  and  DOX in b-e.
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may therefore be a cellular stress response induced by the
antiandrogen.
Far upstream element-binding protein 2 (FBP2) was up-
regulated in the presence of all of the antiandrogens tested,
suggesting that this protein is regulated as part of an inhibi-
tory response. The strongest response was to the pure an-
tagonist bicalutamide, whereas an intermediate response was
observed in the presence of the partial agonists hydroxyflut-
amide and cyproterone acetate. FBP2 is involved in AU-rich
element (ARE)-mediated decay of mRNA species. This post-
transcriptional regulation is important in physiological cellular
proliferation and is a process that has been found to be
deregulated in cancer (43). Additionally, EEF2 was regulated
by all the various treatments used. Functioning as a protein
elongation factor, EEF2 is regulated by a specific kinase
EF2K, which is under the regulation of mTOR (44), indicating
that the mTOR pathway is a point of commonality in all AR
responses and therefore may have an important role in an-
drogen regulated cell growth. The EEF2 protein is inactivated
by phosphorylation, and inactivation of EF2K is increased by
mTOR activity in breast cancer cells (45). Other groups have
shown that up-regulation of mTOR activity occurs following
androgen stimulation of LNCaP cells and in androgen inde-
pendent variants of the LNCaP cell line (46–48). Our data
identified regulation of two EEF2 isoforms, one of which was
up-regulated in cyproterone acetate and hydroxyflutamide
exposed cells, whereas the second was up-regulated in the
presence of all treatments. It may therefore be the case that
EEF2 levels were generally up-regulated in response to treat-
ment, indicating a need for increased translation in all ex-
posed cells irrespective of the nature of the treatment,
whereas the modification may be a specific response to cer-
tain ligands via mTOR regulation of EEF2 kinase.
Our 2D gels showed two close lying spots, each signifi-
cantly down-regulated, one by mibolerone, the other by cy-
proterone acetate and hydroxyflutamide, which were both
identified as DJ-1. DJ-1 has been previously shown to in-
crease AR activity by abrogating binding of the inhibitory
histone deacetylase complex (49) and expression is up-regu-
lated in several cancers, including prostate cancer (50, 51).
The differential regulation of isoforms of DJ-1 by pure agonist
versus partial agonist again suggests that there is not total
FIG. 7. The ligands promote differ-
ent conformations in the AF-2 and
BF-3 surfaces of the AR ligand binding
domain. A, Surface representation of AR
T877A (PDB accession number 1I38)
with the AF-2 and BF-3 regions colored
orange and purple, respectively; B, the
AF-2 region in the superposed struc-
tures of the androgen receptor T877A
variant in complex with DHT (PDB 1I38,
red) (61), cyproterone acetate (PDB
2oz7, blue) (62) and hydroxyflutamide
(PDB 2ax6, green) (63). C, the same su-
perposition showing residues in the
BF-3 region (61–63).
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overlap between the responses to the various ligands used. A
previous study of DJ-1 in LNCaP cells found that protein, but
not mRNA levels were increased after 48 h of treatment with
mibolerone and hydroxyflutamide (52). We also found no
change in the mRNA levels following treatments. This obser-
vation confirms the importance of data obtained at the pro-
teomic level, which would not be apparent from transcript
based studies and suggests that in addition to regulation of
total protein levels, regulation of the isoforms of DJ-1 occurs,
perhaps by post-translational modification. Of the 10 targets
investigated by qPCR, only GLUD1 was regulated at the
transcriptional level. This therefore suggests that the majority
of early targets identified in this study are regulated by the
nongenomic action of the AR. Nongenomic AR signaling is
known to occur within minutes of activation and is mediated
by the cytoplasmic AR, which activates kinase signaling cas-
cades such as mTOR and PI3K (2).
The ability of steroid receptors to accept a variety of ste-
roidal and nonsteroidal compounds as ligands is not unique to
the AR. The transcriptional response of estrogen receptor 
when stimulated by a range of alternative ligands has been
investigated (53). Synthetic ligands for the estrogen receptor
exhibit tissue specific agonist- or antagonist-like activities,
and are thus termed “selective estrogen receptor modulators”
(SERMs) (54, 55). Further, microarray studies of estrogen
receptor -mediated gene expression have demonstrated a
spectrum of responses following exposure to estradiol, the
SERMs tamoxifen and raloxifene and the pure antiestrogen
ICI 182,780 (53). Our data indicates that this may also be true
at the protein level for ART877A. Each ligand promotes regu-
lation of a specific set of proteins, which overlap to incorpo-
rate the proteins commonly regulated between various li-
gands. Frequently the magnitude of response for each protein
was found to vary according to ligand and several of the pro-
teins regulated by one ligand also showed regulation by the
others, although not to a statistically significant degree.
In terms of mechanism, the difference in the level of re-
sponse is likely because of the range of possible conforma-
tional changes in the receptor structure when bound to the
different ligands. Analysis of available crystal structures of the
ART877A ligand binding domain in complex with DHT, cypro-
terone acetate, or hydroxyflutamide identified important dif-
ferences in the orientation of residue side chains that form the
AF-2 and BF3 domains. In agreement with the finding that the
antiandrogens cyproterone acetate and hydroxyflutamide had
the greatest proteomic overlap, generally the conformation of
the AF-2 and BF3 surfaces induced by these ligands was also
similar and differed to that induced by DHT.
The BF3 domain of the AR is an allosteric pocket that has
recently been demonstrated to be the site of interaction for
the cochaperone Bag-1L and has received much interest as a
novel site for therapeutic targeting (30, 32, 56). The AF-2
coactivator interaction groove consists of a hydrophobic cleft
with charge-clamp residues (Lys720 and Glu897) situated at
either end (14, 33). Coactivator interaction motifs can be
broadly separated into two categories: LxxLL-type motifs and
FxxLF-type motifs (where x  any amino acid). The AR pref-
erentially interacts with the latter, because phenylalanine-rich
motifs form electrostatic interactions with both charge-clamp
residues whereas leucine-rich motifs only form hydrogen
bonds with Lys720 (57). Because Glu897 is located on helix
12, which acts as a lid to the ligand-binding pocket, the
positioning of this residue is greatly dependent upon the
ligand bound. Indeed, the crystal structure analysis demon-
strated that this residue adopts a different conformation for
each of the ligands investigated. The AF-2 residues Met734,
Asp731 and Met894 are also known to be important in co-
activator interaction motif binding. The orientation of these
was similar in the cyproterone acetate and hydroxyflutamide
complexes and differed to that induced by DHT. Such con-
formational changes likely in turn affect protein-protein inter-
actions with accessory proteins. We therefore hypothesize
that the differences in protein expression identified here are as
a result of ligand-specific receptor conformations, which pro-
mote different complex formations, subsequently affecting
target regulation.
It follows that a mutant receptor activated by an antiandro-
gen may not elicit the same cellular responses as a wild type
receptor activated by androgen. This implies that, in prostate
cancer, recurrent tumors with a mutant receptor may behave
differently depending on the mutation present and the ligands
available to stimulate growth. Supporting evidence for this
comes from our studies of the putative tumor suppressor
prohibitin. In the presence of mibolerone, prohibitin is down-
regulated. This suggests that loss of prohibitin is important in
androgen-induced growth, in accordance with our previous
data (29). Cyproterone acetate and hydroxyflutamide only
weakly reduced prohibitin levels and hence we believe that
loss of prohibitin is less important for growth induced by these
ligands. In support of this, exogenous expression of prohibitin
was significantly more potent at inhibiting androgen-in-
duced growth compared with cyproterone acetate/hydroxy-
flutamide-induced growth.
Recently, second generation antiandrogens, such as ARN-
509 and Enzalutamide, have entered the clinic or trials (58).
This study is also likely to have relevance to these antiandro-
gens because AR mutations have also been associated with
resistance to these therapies. For example, the AR mutation
resulting in F876L has been associated with ARN-509 and
Enzalutamide failure and identified in the plasma of CRPC
patients (59, 60). We therefore conclude that the AR promotes
differential changes in the proteome dependent upon the
activating ligand and/or the mutation present and these
changes appear to have a bearing on growth.
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